The CHMP recommended granting a marketing authorization for Alyftrek, a medicine intended for the treatment of cystic fibrosis in people aged six years and older who have at least one non class I mutation in the cystic fibrosis transmembrane conductance regulator gene, the EMA announced. Alyftrek is marketed by Vertex Pharmaceuticals (VRTX).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Stock (VRTX) Trending as Q1 Earnings Approach
- Vertex Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald
- QQQ ETF News, 4/16/2025
- Vertex Pharmaceuticals price target raised to $462 from $459 at Morgan Stanley
- Vertex Pharmaceuticals announces EC approval of expanded KAFTRIO label